Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Basit Öğe Kaydı
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridBondarenko, Igor/0000-0002-7071-2471
dc.authoridMUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authorwosidKilickap, Saadettin/AAP-3732-2021
dc.authorwosidBondarenko, Igor/U-5156-2017
dc.authorwosidMUSTAFA, ÖZGÜROĞLU/A-8234-2016
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidZavizion, Viktor/C-2550-2019
dc.authorwosidPaydas, Semra/F-3132-2018
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.date.accessioned2024-06-12T11:09:19Z
dc.date.available2024-06-12T11:09:19Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS101en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3en_US
dc.identifier.startpageS101en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22770
dc.identifier.volume16en_US
dc.identifier.wosWOS:000631349600072en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectAnti-PD-1en_US
dc.subjectCemiplimaben_US
dc.titleClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLCen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu